These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11534926)

  • 1. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Ann Clin Psychiatry; 2001 Jun; 13(2):63-7. PubMed ID: 11534926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Am J Psychiatry; 1992 Aug; 149(8):1053-7. PubMed ID: 1636805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Arch Gen Psychiatry; 1992 Apr; 49(4):318-23. PubMed ID: 1558466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipramine treatment of panic disorder with agoraphobia: the second time around.
    Mavissakalian MR; Perel JM; de Groot C
    J Psychiatr Res; 1993; 27(1):61-8. PubMed ID: 8515390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
    Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
    Marchesi C; Ampollini P; Signifredi R; Maggini C
    Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
    Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
    Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific side effects of long-term imipramine management of panic disorder.
    Mavissakalian M; Perel J; Guo S
    J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
    Barlow DH; Gorman JM; Shear MK; Woods SW
    JAMA; 2000 May; 283(19):2529-36. PubMed ID: 10815116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 15-year follow-up study of patients with panic disorder.
    Andersch S; Hetta J
    Eur Psychiatry; 2003 Dec; 18(8):401-8. PubMed ID: 14680716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance drug therapy of panic disorder.
    Curtis GC; Massana J; Udina C; Ayuso JL; Cassano GB; Perugi G
    J Psychiatr Res; 1993; 27 Suppl 1():127-42. PubMed ID: 8145175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational treatment of panic disorder with antidepressants.
    Mavissakalian MR; Ryan MT
    Ann Clin Psychiatry; 1998 Dec; 10(4):185-95. PubMed ID: 9988061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
    Cox BJ; Endler NS; Lee PS; Swinson RP
    J Behav Ther Exp Psychiatry; 1992 Sep; 23(3):175-82. PubMed ID: 1487535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipramine vs. sertraline in panic disorder: 24-week treatment completers.
    Mavissakalian MR
    Ann Clin Psychiatry; 2003; 15(3-4):171-80. PubMed ID: 14971862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the Panic and Agoraphobia Scale in a clinical trial.
    Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
    Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.